1
Ivanov Vladimir, Nilsson Karl Magnus, Rosenquist Aasa Annica Kristin, Samuelsson Bengt Bertil, Raboisson Pierre Jean Marie Be, de Kock Herman, Vendeville Sandrine Marie Hele, Simmen Kenneth Alan: Hcv ns-3 serine protease inhibitors. Tibotec Pharm, Medivir, January 23, 2008: EP1881001-A1 (15 worldwide citation)

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is


2

3
Vingerhoets Johan Hendrika Joz, Michiels Lieve Emma Jan, Dierynck Inge: Methods for the phenotypic and genotypic assessment of the drug sensitivity of hiv integrase variants. Tibotec Pharm, February 26, 2003: EP1285971-A2 (4 worldwide citation)

The present invention relates to methods and products for the evaluation of HIV treatment. The methods are based on evaluating molecular events at the HIV integrase resulting in altered therapeutic efficacy of the investigated compounds. The methods rely on providing an integrase gene and evaluating ...


4
Stevens Paul Theodoor Agnes, Peeters Jozef, Vandecruys Roger Petrus Gerebe, Stappers Alfred Elisabeth, Copmans Alex Herman: Salt of 4- not not 4- not not 4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile. Janssen Pharmaceutica, Tibotec Pharm, March 8, 2006: EP1632232-A1 (4 worldwide citation)

The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.


5
Kemp Sharon, Vingerhoets Johan Hendrika Jos, Michiels Lieve Emma Jan: Methods and means for assessing hiv envelope inhibitor therapy. Tibotec Pharm, February 12, 2003: EP1283272-A2 (1 worldwide citation)

The present invention relates to methods and products for the evaluation of HIV treatment. In particular, molecular events at the HIV envelope protein and their effect on therapeutic efficacy of drugs are determined. The methods rely on providing HIV envelope nucleic acid material and evaluating a t ...


6
HEERES JAN, LEWI PAULUS JOANNES, JANSSEN PAUL ADRIAAN JAN, LEEMANS RUDOLF, MOENS LUC JOZEF RAPHAEL: HIV inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives, HIV-inhibierende 2-(4-cyanophenylamino)Pyrimidinderivate, Derives de 2-(4-cyanophenyl)pyrimidine utiles pour inhiber le VIH. TIBOTEC PHARM, November 23, 2011: EP2388249-A1

HIV replication inhibitors of formula pharmaceutically acceptable addition salts or stereochemically isomeric forms thereof, wherein X is S, SO or SO 2 the preparation of these compounds as well as pharmaceutical compositions comprising these compounds the use of these compounds for the prevention o ...


7
Xie Dong, Cao Wei, Erickson John W: Methods for determining plasma free drug concentration. Tibotec Pharm, December 11, 2002: EP1265073-A2

The present invention relates to methods for isothermal titration calorimetry analysis of the binding affinity of protease inhibitors to plasma proteins.


8
Xie Dong, Erickson John W, Grulich Paul: Anti-fusion assay. Tibotec Pharm, July 21, 2004: EP1438333-A2

Methods of identifying a fusion inhibitor and inhibitors of gp41-mediated membrane fusion are disclosed. The methods comprise, for example, providing a first helical polypeptide comprising a sequence of IQN17 (SEQ ID NO: 1); providing a second helical polypeptide of 34 or less than 34 amino acids co ...


9

10